Jaime Wheeler

Jaime Wheeler, MBA, CPhT, was appointed Chief Executive Officer of CroíValve in July 2026, taking the helm of the clinical-stage medical device company developing the DUO transcatheter tricuspid coaptation valve system. Wheeler is a transformational healthcare executive with more than 25 years of experience driving innovation at the intersection of clinical excellence and business strategy, bringing deep expertise in bringing novel transcatheter devices to market.

She joins CroíValve after 12 years at Edwards Lifesciences, most recently as Senior Vice President of Global Clinical Affairs for the Transcatheter Heart Valve business unit, where she played a pivotal role in advancing the clinical evidence that shapes transcatheter structural heart care today — most notably the PARTNER trial series. She was the clinical lead on three successful merger and acquisition deals, the largest worth $1.5 billion, and has managed multiple divisions and regions, including an expatriate assignment in Tokyo, Japan.

Wheeler holds a Bachelor of Science degree from Virginia Tech and a Master of Business Administration from Florida Atlantic University. She is a former Virginia State Emergency Medical Technician (EMT-B) and is a Certified Pharmacy Technician (CPhT). She has worked in both medical device and pharmaceutical research focusing on the strategy, design, and conduct of clinical research programs across various therapeutic areas including Cardiology, Rheumatology, Pain Management, Peripheral Vascular/Embolic Protection, and Structural Heart.

Career History

• Chief Executive Officer, CroíValve (July 2026–present)
• Senior Vice President of Global Clinical Affairs, Transcatheter Heart Valves, Edwards Lifesciences (2014–2026)

What Wheeler could bring to CroíValve: Wheeler's appointment positions her to leverage her proven track record in advancing breakthrough structural heart therapies to market. Her extensive clinical research expertise, combined with hands-on experience shepherding complex device development programs and regulatory pathways, makes her well-suited to guide CroíValve through the final clinical trial phases of the DUO System and toward commercialization. Her demonstrated ability to lead complex M&A transactions and manage global divisions suggests capacity to scale the company through its growth trajectory and international expansion.